EP Patent

EP2054036B1 — Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening

Assigned to Singh Broemer And Company Inc · Expires 2019-12-18 · 6y expired

What this patent protects

Patent listed against Cleviprex.

Drugs covered by this patent

Patent Metadata

Patent number
EP2054036B1
Jurisdiction
EP
Classification
—
Expires
2019-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Singh Broemer And Company Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.